- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- PD-1 cDNA followed by PD-1-Ig fusion protein
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- ?g sizes: 0.2 mg/mL?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
SB - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.125 ?g per million cells in 100 ?l volume. For immunofluorescent staining using ?l sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
- Additional Product Notes
Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
- Application References
(PubMed link indicates BioLegend citation) -
- Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
- Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
- Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
- Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
- Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
- Ogbechi J, et al. 2022. Front Immunol. 13:1001956. PubMed
- Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
- Clemmensen HS, et al. 2021. MBio. 12:. PubMed
- Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
- Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
- Wei SC, et al. 2019. Immunity. 50:1084. PubMed
- Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed
- Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
- Clemmensen HS, et al. 2020. Front Immunol. 11:585359. PubMed
- Calvo-Barreiro L, et al. 2021. Neurotherapeutics. . PubMed
- Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
- Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
- Wong HS, et al. 2021. Cell. . PubMed
- Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
- Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
- Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
- Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
- Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
- Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
- Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
- RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed
- Watson MJ, et al. 2021. Nature. 591:645. PubMed
- Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
- Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
- Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
- Papa I, et al. 2017. Nature. 547:318. PubMed
- He C, et al. 2022. Nat Commun. 13:5459. PubMed
- Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
- Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
- Mulens-Arias V, et al. 2022. Pharmaceutics. 14:. PubMed
- Amobi-McCloud A, et al. 2021. Front Immunol. 12:678999. PubMed
- Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
- Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
- Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
- Kinsey G, et al. 2012. J Am Soc Nephrol. 23:1528. PubMed
- Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
- Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
- Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
- Scala M, et al. 2016. J Virol. 90: 8563 - 8574. PubMed
- Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
- Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
- RRID
- AB_10900085 (BioLegend Cat. No. 135217) AB_2562568 (BioLegend Cat. No. 135221) AB_2561447 (BioLegend Cat. No. 135218)
